Exact Sciences (EXAS)’s Insider Thomas Carey Sells 8,448 Shares; Shorts at Thl Credit (TCRD) Raised By 3.39%

April 13, 2018 - By rebbecca

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Thl Credit Inc (NASDAQ:TCRD) had an increase of 3.39% in short interest. TCRD’s SI was 293,000 shares in April as released by FINRA. Its up 3.39% from 283,400 shares previously. With 103,100 avg volume, 3 days are for Thl Credit Inc (NASDAQ:TCRD)’s short sellers to cover TCRD’s short positions. The stock increased 0.13% or $0.01 during the last trading session, reaching $7.89. About 92,888 shares traded. THL Credit, Inc. (NASDAQ:TCRD) has declined 19.69% since April 13, 2017 and is downtrending. It has underperformed by 31.24% the S&P500.

Since March 9, 2018, it had 4 buys, and 3 selling transactions for $900,863 activity. The insider Rusnak-Carlson Sabrina bought 1 shares worth $8. Tillinghast Sam W. also sold $327,582 worth of THL Credit, Inc. (NASDAQ:TCRD) shares. Shares for $124,344 were bought by Fellows James R. Another trade for 1,500 shares valued at $12,336 was bought by Flynn Christopher J.. $10,263 worth of stock was bought by Olson Terrence W. on Monday, March 12.

Investors sentiment increased to 0.97 in Q4 2017. Its up 0.01, from 0.96 in 2017Q3. It is positive, as 8 investors sold THL Credit, Inc. shares while 21 reduced holdings. 9 funds opened positions while 19 raised stakes. 11.98 million shares or 2.10% more from 11.74 million shares in 2017Q3 were reported. Tradewinds Cap Management Ltd Liability Co holds 0% of its portfolio in THL Credit, Inc. (NASDAQ:TCRD) for 500 shares. Fort Washington Investment Advisors Inc Oh invested in 0.02% or 185,734 shares. Guggenheim Limited Liability Company holds 233,963 shares. Invesco reported 982,018 shares. Manufacturers Life Co The has invested 0% in THL Credit, Inc. (NASDAQ:TCRD). First Allied Advisory Serv, a Missouri-based fund reported 11,510 shares. Lsv Asset accumulated 685,442 shares. Janney Montgomery Scott Ltd reported 0% of its portfolio in THL Credit, Inc. (NASDAQ:TCRD). Fiera Capital Corporation owns 450,417 shares or 0.02% of their US portfolio. Moreover, Blackrock has 0% invested in THL Credit, Inc. (NASDAQ:TCRD) for 199,397 shares. Eaton Vance Mgmt holds 0% or 67,000 shares in its portfolio. Howe Rusling Inc invested 0% of its portfolio in THL Credit, Inc. (NASDAQ:TCRD). Freestone Cap Hldgs Ltd Liability Corporation owns 285,321 shares for 0.18% of their portfolio. Stephens Ar reported 0.01% of its portfolio in THL Credit, Inc. (NASDAQ:TCRD). The New York-based Omega Incorporated has invested 0.05% in THL Credit, Inc. (NASDAQ:TCRD).

Among 8 analysts covering THL Credit (NASDAQ:TCRD), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. THL Credit had 26 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Hold” rating by Maxim Group on Thursday, March 8. The rating was maintained by Deutsche Bank on Thursday, August 11 with “Buy”. Janney Capital initiated THL Credit, Inc. (NASDAQ:TCRD) rating on Friday, June 17. Janney Capital has “Neutral” rating and $12 target. The firm earned “Hold” rating on Tuesday, August 11 by Zacks. The firm earned “Outperform” rating on Monday, April 4 by Wells Fargo. The firm earned “Hold” rating on Friday, September 15 by Keefe Bruyette & Woods. Deutsche Bank maintained THL Credit, Inc. (NASDAQ:TCRD) rating on Tuesday, August 11. Deutsche Bank has “Buy” rating and $14.50 target. The company was maintained on Monday, November 9 by Maxim Group. The rating was maintained by Jefferies on Friday, November 3 with “Hold”. Keefe Bruyette & Woods maintained THL Credit, Inc. (NASDAQ:TCRD) rating on Monday, August 14. Keefe Bruyette & Woods has “Hold” rating and $10.5 target.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $5.52 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

After the publishing of a public document filled with Washington-based Security and Exchange Commission; a insider deal became apparent. The director of Exact Sciences Corp, Thomas Carey; made a trade in the open market by selling 8,448 shares at an average cost of $39.7 of the public company having a total value of $335,630 U.S. Dollars. Thomas Carey right now has in hand 52,410 shares or 0.04% of Exact Sciences Corp’s market cap.

Among 18 analysts covering EXACT Sciences (NASDAQ:EXAS), 11 have Buy rating, 1 Sell and 6 Hold. Therefore 61% are positive. EXACT Sciences has $67.0 highest and $4 lowest target. $42.88’s average target is -6.05% below currents $45.64 stock price. EXACT Sciences had 74 analyst reports since July 24, 2015 according to SRatingsIntel. Benchmark maintained it with “Buy” rating and $60.0 target in Tuesday, October 31 report. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Wednesday, May 31 by Cowen & Co. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Thursday, March 29 by William Blair. The rating was maintained by Canaccord Genuity on Tuesday, October 3 with “Buy”. Roth Capital maintained it with “Buy” rating and $4600 target in Wednesday, July 26 report. The rating was maintained by Jefferies on Tuesday, July 4 with “Buy”. The stock has “Buy” rating by Canaccord Genuity on Tuesday, October 31. The firm earned “Buy” rating on Thursday, October 1 by Craig Hallum. The firm earned “Outperform” rating on Tuesday, October 31 by Robert W. Baird. The firm has “Neutral” rating given on Thursday, October 8 by Wedbush.

Investors sentiment decreased to 0.88 in 2017 Q4. Its down 0.13, from 1.01 in 2017Q3. It turned negative, as 25 investors sold Exact Sciences Corporation shares while 105 reduced holdings. 44 funds opened positions while 70 raised stakes. 92.48 million shares or 1.24% less from 93.65 million shares in 2017Q3 were reported. Tci Wealth Advisors holds 0% or 68 shares. Credit Suisse Ag reported 0.02% stake. 13,665 are owned by Rmb Capital Mgmt Ltd Liability. Sectoral Asset Management stated it has 1.26% in Exact Sciences Corporation (NASDAQ:EXAS). Salem Investment Counselors has 6,480 shares for 0.04% of their portfolio. Wells Fargo And Com Mn, a California-based fund reported 468,384 shares. Dimensional Fund Advsr L P owns 224,953 shares. Deutsche National Bank Ag holds 375,659 shares or 0.01% of its portfolio. Massachusetts Ma has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Ifc Holding Fl has invested 0.13% in Exact Sciences Corporation (NASDAQ:EXAS). Jpmorgan Chase & holds 0.03% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS) for 2.72M shares. Aperio Gp Ltd Liability holds 14,017 shares or 0% of its portfolio. Los Angeles Management & Equity Research Incorporated reported 76,142 shares. Eventide Asset Mngmt Limited Company reported 100,000 shares or 0.27% of all its holdings. Biondo Advsr Ltd Limited Liability Company holds 1.26% in Exact Sciences Corporation (NASDAQ:EXAS) or 94,735 shares.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on April, 26. They expect $-0.35 EPS, down 9.37% or $0.03 from last year’s $-0.32 per share. After $-0.18 actual EPS reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 94.44% negative EPS growth.

THL Credit, Inc. (NASDAQ:TCRD) Institutional Positions Chart